ClinicalTrials.gg
CompletedNCT04836988Updated Oct 4, 2023

Face to Face or Digitally Delivered First-line Osteoarthritis Treatment?

An observational study in Hip Osteoarthritis and Knee Osteoarthritis, sponsored by Lund University. Completed at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-04.

Sponsored by Lund University · Observational

Study type
Observational
Model
Case-only
Time perspective
Other
Enrollment
6,946
Ages
18 Years and older
Sex
All
01

Study summary

This study will compare outcomes of two different delivery methods (Face-to-face and digitally) of first-line treatment for hip and knee osteoarthritis.

Read the detailed description

According to international guidelines, exercise and education should constitute the first-line intervention for people with knee and hip osteoarthritis (OA) and have been shown to be effective in reducing OA symptoms regardless of disease severity. To implement those guidelines, the Better Management of Patients with OsteoArthritis (BOA), a face-to-face concept including education and an option to exercise, has been developed and are offered at primary care clinics in Sweden since 2008. However, traditional face to face interventions present barriers, such as limited access and lack of flexibility, which may limit the patients' adherence with the interventions. In an effort to overcome such barriers, a digital self-management program (Joint Academy) that is based on the BOA concept started in 2014. Although, both delivering methods have been reported to reduce OA symptoms in patients with hip and/or knee OA, little is known whether the results of digital interventions are comparable with traditional face-to-face rehabilitation programs. In this retrospective register-based study we will compare the outcomes of the two different modalities of first-line treatment delivery (face-to-face vs digitally) after 3 months program participation using data from the BOA and Joint Academy registers. Main outcome will be self-reported change in pain between baseline and three months follow-up and secondary outcomes will be change in self-reported walking difficulties, willingness for joint surgery and health-related quality of life between baseline and three months follow-up.

Statistical analysis In this study we will include all participants in the digital program fulfilling the eligibility criteria outlined below (n >2000). These participants will be matched 1:1 to participants in the BOA register using the propensity scoring approach. The minimum clinically important difference is typically considered to be one unit on a 0-10 NRS scale. To obtain a 95% confidence interval for the between-group difference with a width of at most 0.5 units (i.e. very precise) in a sample with a typical standard deviation of 1.5, with 99% probability, we will need \~630 patients in total.

We will use observational data to emulate an equivalence trial comparing the effect on joint pain of a digitally delivered first-line intervention and of an in-person delivered first line intervention for people with OA of the hip or knee. In order to establish equivalence between the interventions the pain change after the intervention should differ of less than 1-point on a 0-10 NRS pain scale. This cut off was selected based on previous work identifying 1-point change as the MCID in people with OA. The main outcome will be analyzed using a propensity score matching approach. We will estimate the propensity score using a logistic regression model, in which we will regress the treatment status on the observed baseline characteristics of the participants. The characteristics to include in the propensity score will be selected using the disjunctive cause criteria, including factors in the analysis identified as causes of treatment allocation(exposure) and/or the pain change (outcome). We will use nearest neighbor matching to select controls (BOA participants) whose propensity score is closest to that of the treated subject. Furthermore, we will use an optimal matching strategy to minimize the total within-pair difference of the propensity score. Within-pair differences in main outcome will be analysed using a paired t-test. Finally, we will adjust the analysis for baseline pain in order to increase the precision of the estimates and minimize the regression to the mean effect

02

Conditions studied

  • Hip Osteoarthritis
  • Knee Osteoarthritis
03

In context

Osteoarthritis, Hip

642 studies on the registry are indexed under Osteoarthritis, Hip; 122 are open to participants now.

This study's enrollment of 6,946 is above the median of 135 across 159 observational studies indexed under Osteoarthritis, Hip.

Browse Osteoarthritis, Hip studies →

Lead sponsor

Lund University is the lead sponsor of 234 studies on the registry; 36 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals with a clinical diagnosis of hip or knee osteoarthritis that have participated for three months in either digitally or face-to-face osteoarthritis management will be included

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A clinical diagnosis of hip or knee OA
  • Participated for three months in any of the programs between 2018-04-01 and 2020- 03-31
  • Reported pain at both baseline and at 3 months follow-up
  • Adherence of ≥80%, i.e., ≥80% completed education videos, exercises and questionnaires offered in the digital program and participation in two out of three educational lessons and at least 10 of the 12 supervised group exercise sessions offered in the BOA.

Exclusion criteria

Exclusion Criteria

  • None
05

Study design

Observational model
Case-only
Time perspective
Other
Enrollment
6,946 participants (actual)
Target follow-up
3 Months
Patient registry
Yes

Groups and cohorts

  • Digitally delivered osteoarthritis treatment

    Participants enrolled in the digitally delivered osteoarthritis managament program (Joint Academy register)

    Other: Three months of digitally delivered osteoarthritis treatment

  • Face-to-face delivered osteoarthritis treatment

    Participants enrolled in the face-to-face delivered osteoarthritis managament program (BOA-register)

    Other: Three months of face-to-face delivered osteoarthritis treatment

Interventions

  • OtherThree months of digitally delivered osteoarthritis treatment

    Digitally delivered osteoarthritis management including education and exercise and weight control if needed

  • OtherThree months of face-to-face delivered osteoarthritis treatment

    Face-toface delivered osteoarthritis management including education and exercise and weight control if needed

06

What researchers measure

Primary outcomes

  1. Pain assessed with the Numeric Rating Scale (NRS)

    The NRS comprises an 11-point scale where 0 indicates no pain and 10 indicates the worst possible pain.

    Time frame: Change from baseline to three months

Secondary outcomes

  1. Walking difficulties

    Dihotomous reply, yes/no

    Time frame: Change from baseline to three months

  2. Willingness for surgery

    Dihotomous reply, yes/no

    Time frame: Change from baseline to three months

  3. Health-related quality of life

    Healt-related quality of life will be assessed with the EuroQol - 5 dimension descriptive system (EQ-5D-3L) (Index 0-1). A higher EQ-5D-3L index indicates better health-related quality of life.

    Time frame: Change from baseline to three months

07

Study locations

1 site
  • Lund University
    Lund, Skåne County 22100, Sweden
08

References and documents

Study documents

  • Statistical analysis plan · Apr 14, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — De-identified IPD for primary and secondary outcomes will be made available upon reasonable request.

Supporting information: Statistical analysis plan

Time frame: SAP is available at Lund University website: https://lucris.lub.lu.se/admin/editor/dk/atira/pure/modules/unifiedprojectmodel/external/model/project/editor/upmprojecteditor.xhtml?id=97180259

Data sharing details ↗ · lucris.lub.lu.se

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Mar 2021, 0 months.

Of 51 non-industry observational studies under Osteoarthritis, Hip, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 59. This study's 0 months is below that.

Counting every sponsor, half of 82 studies reached it within 55 months; a quarter within 14 and three quarters within 113.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2021
First posted
Apr 8, 2021
StartActual
Mar 6, 2021
Primary completionActual
Mar 30, 2021
CompletionActual
Mar 30, 2021
Last update
Oct 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04836988
Lead sponsor
Lund University
Responsible party
Sponsor
First posted
Apr 8, 2021
Start date
Mar 6, 2021
Primary completion
Mar 30, 2021
Completion
Mar 30, 2021
Last update
Oct 4, 2023

Study contacts

Anna Cronström
principal investigator · Lund University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion